Global nuclear medicine / radiopharmaceuticals market to be worth $7.27 Billion by 2021 at CAGR of 9.3 percent: report
Press releases may be edited for formatting or style | October 25, 2016
Molecular Imaging
PUNE, India, October 25, 2016 /PRNewswire/ -- According to a new market research report "Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021", published by MarketsandMarkets, This report studies the global Nuclear Medicine/Radiopharmaceuticals Market for the forecast period of 2016 to 2021. This market is expected to reach USD 7.27 Billion by 2021 from USD 4.67 Billion in 2016, growing at a CAGR of 9.3%.
Browse 271 market data Tables and 49 Figures spread through 281 Pages and in-depth TOC on "Nuclear Medicine/Radiopharmaceuticals Market"
http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html
Early buyers will receive 10% customization on this report.
The global Nuclear Medicine/Radiopharmaceuticals Market is segmented on the basis of type, application, procedural volume, and region.
Based on type, the Nuclear Medicine/Radiopharmaceuticals Market is categorized into diagnostic and therapeutic radioisotopes. In 2016, the diagnostic segment accounted for a major share of the Nuclear Medicine/Radiopharmaceuticals Market. On the basis of diagnostic radiopharmaceuticals, the Nuclear Medicine/Radiopharmaceuticals Market is further segmented into SPECT and PET radioisotopes. In 2016, the SPECT segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals diagnostic radiopharmaceuticals market. Based on therapeutic radiopharmaceuticals, the market is further segmented into beta emitters, alpha emitters, and brachytherapy. In 2016, the beta emitters segment accounted for the largest share of the market.
Based on application, the Nuclear Medicine/Radiopharmaceuticals Market is segmented into SPECT, PET, and therapeutic applications. In 2016, the cardiology application segment accounted for the largest share of the nuclear medicine SPECT applications market. The nuclear medicine/radiopharmaceuticals PET applications market was dominated by the oncology segment, while the nuclear medicine/radiopharmaceuticals therapeutic applications market was dominated by the thyroid application segment.
Based on region, the Nuclear Medicine/Radiopharmaceuticals Market is divided into North America, Europe, Asia-Pacific, and RoW. The RoW region comprises Latin America, the Middle East and Africa. In 2016, North America accounted for the largest share of the Nuclear Medicine/Radiopharmaceuticals Market, followed by Asia-Pacific and Europe.
|
|
|
You Must Be Logged In To Post A Comment
|
